[O13] Oral Session 13　呼吸器3（希少な遺伝子変異）
【E】

[O13-3] Primary Data from DESTINY-Lung01: A Phase 2 Trial of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

^○後藤 悌¹, T. Li Bob², F. Smit Egbert³, 中川 和彦⁴, 宇田川 響⁵, Mazières Julien⁶, Nagasaka Misako⁷, Bazhenova Lyudmila⁸, Saltos Andreas N.⁹, Felip Enriqueta¹⁰, Pacheco Jose M.¹¹, Pérol Maurice¹², Paz-Ares Luis¹³, Saxena Kapil¹⁴, 志賀 遼太¹⁴, Cheng Yingkai¹⁴, Acharyya Suddhasatta¹⁴, Shahidi Javad¹⁴, Planchard David¹⁵, A. Jänne Pasi¹⁶ (1.国立がん研究センター中央病院, 2.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 3.Netherlands Cancer Institute, Amsterdam, Netherlands, 4.近畿大学病院, 5.国立がん研究センター東病院, 6.Institut Universitaire du Cancer, Toulouse, France, 7.Karmanos Cancer Institute, Detroit, MI, USA, 8.University of California San Diego Moores Cancer Center, San Diego, CA, USA, 9.Moffitt Cancer Center, Tampa, FL, USA, 10.Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, 11.University of Colorado, Aurora, CO, USA, 12.Centre Léon Bérard, Lyon, France, 13.Hospital Universitario 12 de Octubre, Madrid, Spain, 14.Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 15.Gustave Roussy, Villejuif, France, 16.Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, USA)